Nuvilex Teaches Wall Street a Lesson in M&A BALTIMORE,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nuvilex Teaches Wall Street a Lesson in M&A

BALTIMORE, MD--(Marketwired - Jul 17, 2013) - In a newly released research update, Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes in a recent article on its website that after reviewing the structure of Nuvilex's ( OTCQB : NVLX ) recently announced acquisition, the Company has demonstrated it can teach Wall Street a lesson or two in how to execute M&A.

As a result of the aforementioned acquisition, Nuvilex now owns exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment. Plus, these licenses include worldwide rights to utilize the live-cell encapsulation platform technology to develop treatments for any and all cancer types, regardless of the cell type encapsulated. 

It should be noted that it is not uncommon for small biotechs to acquire intellectual property via license. However, many firms make the common mistake of biting off more than they can chew as the management team's collective eyes get big in anticipation of all of the benefits a license execution can offer. These firms invariably acquire associated entities or non-core assets in conjunction with an exclusive IP license that too often doom the firms that are run by scientists and not operators, and the end result is an ugly mess, with no access to capital.

In the case of Nuvilex, management originally intended to go down the path of acquiring the entity that owned the subsidiary that owned the IP. It could have been clean and simple and would have also meant acquiring senior personnel, overhead, and unrelated costs. Moreover, such a deal would have likely required greater investment dollars (and 100M shares) which would have resulted in substantial dilution.

By taking a very slow and steady approach, and focusing on the most critical piece of the acquisition (exclusive license) instead of becoming too big too soon (by acquiring the entity), management executed a great deal for shareholders.

Now, shareholders in Nuvilex own the exclusive rights to a highly efficacious oncology treatment platform that may be used to treat multiple forms of cancer, based upon tremendous Phase II clinical trial results. Moreover, by demonstrating prudence and patience, the Company should be able to increase its product treatment arsenal and attract new partners and investors, as needed. Therefore, with the wind at its back, and a history of clinical and M&A success, shareholders appear primed to be rewarded with higher stock prices in the future.

To view Nuvilex reports and articles and to view our disclaimer, please visit www.goldmanresearch.com .

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com .

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com .

About Nuvilex, Inc. ( OTCQB : NVLX ): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com .

Goldman Small Cap Research Rob Goldman Analyst 410-609-7100 rob@goldmanresearch.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 157

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 227

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 111

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 182

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 26

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 135

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading

Top 5 Most Recently Viewed Articles

Social Media Buzz Powers Hainan's Travel Boom

Updated Category News Views 205

Social Media Buzz Powers Hainan's Travel Boom This year marks a remarkable shift in Hainan's tourism, driven by the advent of visa-free travel access for international visitors. As the beautiful island in southern China opens its doors wider, a surge in travelers, especially travel bloggers from around the globe, is noticeable. Influencers from diverse backgrounds,...

Continue Reading
Kodiak Sciences Reports Q3 2025 Financial Milestones and Updates

Updated Category News Views 375

Kodiak Sciences Reports Q3 2025 Financial Milestones and Updates Kodiak Sciences Inc. (Nasdaq: KOD) has recently shared significant business highlights along with financial results for the third quarter of 2025. This biotechnology company is making strides in the field of retinal medicine. 'We are witnessing a period marked by sustained momentum,' expressed Victor...

Continue Reading
Vaisala Initiates Share Repurchase Program to Enhance Incentives

Updated Category News Views 193

Vaisala’s Strategy for Share Repurchases Vaisala Corporation is embarking on an important journey to repurchase its own shares as part of a broader incentive plan. This strategic decision follows the authorization granted by the Annual General Meeting, reflecting the company's commitment to fostering a rewarding environment for its employees. As a key player in climate...

Continue Reading
Investigating Customer Bancorp, Inc. Losses: Understand Your Rights

Updated Category News Views 92

Exploring Customers Bancorp, Inc.'s Recent Challenges Customers Bancorp, Inc., identified by the ticker CUBI, is dealing with significant accusations regarding the truthfulness of the business information it has shared with the public. The Rosen Law Firm, a respected advocate for investor rights, is currently looking into securities claims tied to these allegations. If...

Continue Reading
Allurity and Onevinn: Transforming Cybersecurity Together

Updated Category News Views 374

Allurity Expands its Cybersecurity Portfolio with Onevinn Acquisition Allurity, a prominent European provider of cybersecurity services, has exciting news to share. The company has taken a significant step forward by acquiring Onevinn, a Swedish company renowned for its intelligent security and managed services. This move not only showcases Allurity's ambitions but also...

Continue Reading